GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » E10

CymaBay Therapeutics (CymaBay Therapeutics) E10 : $-1.56 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

CymaBay Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.370. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.56 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-05), CymaBay Therapeutics's current stock price is $32.48. CymaBay Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-1.56. CymaBay Therapeutics's Shiller PE Ratio of today is .


CymaBay Therapeutics E10 Historical Data

The historical data trend for CymaBay Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CymaBay Therapeutics E10 Chart

CymaBay Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -1.37 -1.56

CymaBay Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -1.37 -1.34 -1.78 -1.56

Competitive Comparison of CymaBay Therapeutics's E10

For the Biotechnology subindustry, CymaBay Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CymaBay Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's Shiller PE Ratio falls into.



CymaBay Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CymaBay Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.37/129.4194*129.4194
=-0.370

Current CPI (Dec. 2023) = 129.4194.

CymaBay Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -1.020 99.695 -1.324
201406 -0.560 100.560 -0.721
201409 -0.440 100.428 -0.567
201412 -0.930 99.070 -1.215
201503 -0.440 99.621 -0.572
201506 -0.090 100.684 -0.116
201509 -0.270 100.392 -0.348
201512 -0.270 99.792 -0.350
201603 -0.290 100.470 -0.374
201606 -0.300 101.688 -0.382
201609 -0.250 101.861 -0.318
201612 -0.300 101.863 -0.381
201703 -0.200 102.862 -0.252
201706 -0.310 103.349 -0.388
201709 -0.210 104.136 -0.261
201712 -0.080 104.011 -0.100
201803 -0.320 105.290 -0.393
201806 -0.300 106.317 -0.365
201809 -0.340 106.507 -0.413
201812 -0.330 105.998 -0.403
201903 -0.370 107.251 -0.446
201906 -0.350 108.070 -0.419
201909 -0.380 108.329 -0.454
201912 -0.430 108.420 -0.513
202003 -0.190 108.902 -0.226
202006 -0.160 108.767 -0.190
202009 -0.170 109.815 -0.200
202012 -0.230 109.897 -0.271
202103 -0.250 111.754 -0.290
202106 -0.340 114.631 -0.384
202109 -0.330 115.734 -0.369
202112 -0.350 117.630 -0.385
202203 -0.320 121.301 -0.341
202206 -0.310 125.017 -0.321
202209 -0.280 125.227 -0.289
202212 -0.300 125.222 -0.310
202303 -0.290 127.348 -0.295
202306 -0.010 128.729 -0.010
202309 -0.320 129.860 -0.319
202312 -0.370 129.419 -0.370

Add all the adjusted EPS together and divide 10 will get our e10.


CymaBay Therapeutics  (NAS:CBAY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


CymaBay Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Traded in Other Exchanges
Address
7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Executives
Charles Mcwherter officer: Chief Scientific Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold officer: Vice President, Finance C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan officer: General Counsel C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling director C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah director, officer: Chief Executive Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster director 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam officer: Chief Financial Officer 7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim officer: Chief Medical Officer C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans director
Lewis J Stuart officer: Chief Commercial Officer 3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc 10 percent owner 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh 10 percent owner C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103

CymaBay Therapeutics (CymaBay Therapeutics) Headlines

From GuruFocus